
Tan Reviews Updates on T-DXd in HER2-Low and -Ultralow Metastatic Breast Cancer
How has practice recently changed for patients with metastatic hormone receptor–positive, HER2-negative breast cancer? Antoinette Tan, MD, MHS: The NCCN guidelines…are a revolving door. They keep changing. But as of [January], when you look at systemic …